Indications and administration practices amongst medical cannabis healthcare providers: a cross-sectional survey

@article{Corroon2019IndicationsAA,
  title={Indications and administration practices amongst medical cannabis healthcare providers: a cross-sectional survey},
  author={Jamie Corroon and M. Sexton and R. Bradley},
  journal={BMC Family Practice},
  year={2019},
  volume={20}
}
BackgroundThe medical use of cannabis has been legislatively restricted for decades in the US and abroad. In recent years, changing local and national policies have given rise to a community of healthcare providers who may be recommending the medical use of cannabis without the benefit of formal clinical practice guidelines or sufficient training and education. In addition, a citizen science movement has emerged whereby unlicensed and untrained individuals are acting as healthcare provider… Expand
Knowledge, attitudes, and prescribing patterns of cannabis and cannabinoid-containing medicines among European healthcare workers: a systematic literature review.
TLDR
For most European countries, there could not identify any studies evaluating HCPs' knowledge and attitudes towards medicinal cannabis, and available evidence demonstrates a need to provide medical training to the H CPs in Europe regarding medical applications of cannabinoids. Expand
Specific Compositions of Cannabis sativa Compounds Have Cytotoxic Activity and Inhibit Motility and Colony Formation of Human Glioblastoma Cells In Vitro
TLDR
Fractions of a high-THC cannabis strain extract had significant cytotoxic activity against GBM cell lines and glioma stem cells derived from tumor specimens, suggesting that the cannabis treatments may have the potential for preventing the formation of GBM neurospheres associated with the high resistance to current therapies. Expand
Δ9–tetrahydrocannabinol (THC)-rich compositions from canna- bis have cytotoxic activity against ovarian cancer cells and act synergistically with niraparib in vitro
Ovarian cancer (OC) is the most lethal gynecologic malignancy. Cannabis sativa is being used to treat different medical conditions. We sought to examine the effectiveness of combinations of cannabisExpand
Analyzing cannabinoid-induced abnormal behavior in a zebrafish model
TLDR
The behavioral effects of marijuana depend on the ratio of the two different cannabinoid properties, and the repeated light and dark test might be a suitable method for drug-induced behavioral assay. Expand
Analyzing cannabinoid-induced abnormal behavior in a zebrafish model
TLDR
The behavioral effects of the two cannabinoids cannabidiol and WIN55,212–2 appear to be ratio dependent, and the repeated light and dark test could serve as a suitable method for assaying drug-induced behavior. Expand

References

SHOWING 1-10 OF 45 REFERENCES
A Cross-Sectional Survey of Medical Cannabis Users: Patterns of Use and Perceived Efficacy
TLDR
While patient-reported outcomes favor strong efficacy for a broad range of symptoms, many medical users are using Cannabis without physician supervision and for conditions for which there is no formal research to support the use of Cannabis (e.g., depression and anxiety). Expand
Cannabis in medicine: a national educational needs assessment among Canadian physicians
TLDR
Several key educational needs among Canadian physicians regarding CTP are identified and these data can be used to develop resources and educational programs to support clinicians in this area, as well as to guide further research to inform these gaps. Expand
Cannabis as a substitute for prescription drugs – a cross-sectional study
TLDR
Patient-reported outcomes support prior research that individuals are using cannabis as a substitute for prescription drugs, particularly, narcotics/opioids, and independent of whether they identify themselves as medical or non-medical users. Expand
Training and Practices of Cannabis Dispensary Staff
TLDR
Although many dispensary staff are making recommendations consistent with current evidence, some are recommending cannabis that has either not been shown effective for, or could exacerbate, a patient's condition. Expand
A Cross-Sectional Study of Cannabidiol Users
TLDR
Consumers are using CBD as a specific therapy for multiple diverse medical conditions—particularly pain, anxiety, depression, and sleep disorders, and these data provide a compelling rationale for further research to better understand the therapeutic potential of CBD. Expand
Associations between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study
TLDR
The clinically and statistically significant evidence of an association between MCP enrollment and opioid prescription cessation and reductions and improved quality of life warrants further investigations on cannabis as a potential alternative to prescription opioids for treating chronic pain. Expand
Recommendations From Cannabis Dispensaries About First-Trimester Cannabis Use.
TLDR
Nearly 70% of Colorado cannabis dispensaries contacted recommended cannabis products to treat nausea in the first trimester, and as cannabis legalization expands, policy and education efforts should involve dispensaries. Expand
Practical considerations in medical cannabis administration and dosing.
TLDR
Suggestions are offered on cannabis-drug interactions, patient monitoring, and standards of care, while special cases for cannabis therapeutics are addressed: epilepsy, cancer palliation and primary treatment, chronic pain, use in the elderly, Parkinson disease, paediatrics, with concomitant opioids, and in relation to driving and hazardous activities. Expand
Medical Decision-Making Processes and Online Behaviors Among Cannabis Dispensary Staff
TLDR
Budtenders who are formally trained exhibit significantly different patterns of interaction with medical cannabis patients after the introduction of regulations under the newly passed Proposition 64 that permits recreational cannabis use in California. Expand
Adverse effects of medical cannabinoids: a systematic review
TLDR
Short-term use of existing medical cannabinoids appeared to increase the risk of nonserious adverse events, and high-quality trials of long-term exposure are required to further characterize safety issues related to the use of medical cannabinoids. Expand
...
1
2
3
4
5
...